Department of Infection and Immunity, King Faisal Specialist Hospital and Research Center, Riyadh 11564, Saudi Arabia.
Department of Botany and Microbiology, College of Science, King Saud University, Riyadh 11564, Saudi Arabia.
Viruses. 2022 Dec 30;15(1):109. doi: 10.3390/v15010109.
Cervical cancer is the eighth most frequent cancer in Saudi Arabia, and most cases are associated with human papillomavirus (HPV) types 16 and 18. HPV-induced carcinogenesis may be associated with the intra-type variant, genetic mutation, or the continuous expression of viral oncogenes E6 and E7. Infection efficiency and virus antigenicity may be affected by changes in the L1 gene. Thus, this retrospective cohort study analyzed E6, E7, and L1 gene mutations in cervical specimens collected from Saudi women positive for HPV16 or HPV18 infection. HPV16 and HPV18 lineages in these specimens were predominantly from Europe. The L83V mutation in the E6 gene of HPV16 showed sufficient oncogenic potential for progression to cervical cancer. By contrast, the L28F mutation in the E7 gene of HPV16 was associated with a low risk of cervical cancer. Other specific HPV16 and HPV18 mutations were associated with an increased risk of cancer, cancer progression, viral load, and age. Four novel mutations, K53T, K53N, R365P, and K443N, were identified in the L1 gene of HPV16. These findings for HPV16 and HPV18 lineages and mutations in the E6, E7, and L1 genes among women in Saudi Arabia may inform the design and development of effective molecular diagnostic tests and vaccination strategies for the Saudi population.
在沙特阿拉伯，宫颈癌是第八大常见癌症，大多数病例与人类乳头瘤病毒（HPV）16 型和 18 型有关。HPV 引起的癌变可能与同型内变异、基因突变或病毒癌基因 E6 和 E7 的持续表达有关。L1 基因的变化可能会影响感染效率和病毒抗原性。因此，这项回顾性队列研究分析了沙特 HPV16 或 HPV18 感染阳性妇女宫颈标本中 E6、E7 和 L1 基因的突变。这些标本中的 HPV16 和 HPV18 谱系主要来自欧洲。HPV16 的 E6 基因中的 L83V 突变具有足够的致癌潜能，可进展为宫颈癌。相比之下，HPV16 的 E7 基因中的 L28F 突变与宫颈癌的低风险相关。其他特定的 HPV16 和 HPV18 突变与癌症风险增加、癌症进展、病毒载量和年龄有关。在 HPV16 的 L1 基因中发现了四个新的突变，即 K53T、K53N、R365P 和 K443N。这些在沙特妇女中 HPV16 和 HPV18 谱系以及 E6、E7 和 L1 基因中的突变的发现，可能为沙特人群设计和开发有效的分子诊断测试和疫苗接种策略提供信息。
